Photo credit: fernandozhiminaicela / pixabay.com
The European Medicines Agency (EMA) has started the procedure for the examination of the Russian vaccine against coronavirus infection, Sputnik V, RIA Novosti reports. As explained in the Russian Direct Investment Fund (RDIF), the EMA experts will study whether the vaccine meets the EU standards for efficacy, safety and quality.
The decision to start the sequential examination procedure was made taking into account the results of laboratory and clinical studies of the vaccine in adults.
According to the creators of the drug, they are looking forward to the visit of European inspectors to the sites where Sputnik V is produced. Only by combining efforts and discarding politics can one win the fight against the dangerous disease, the developers of the Russian vaccine are sure.
If the European Commission issues a marketing authorization for the vaccine, Sputnik V will be supplied to the European Union. In Brussels, even before the first approved coronavirus vaccines appeared, it was decided to purchase them.
The vaccine has been registered in more than 40 countries with a total population of over one billion people.
Russkiy Mir
